{
    "nct_id": "NCT04288726",
    "official_title": "A Phase 1 Study Evaluating the Safety and Activity of Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes (CD30.CAR-EBVSTs) in Patients with Relapsed or Refractory CD30-Positive Lymphomas",
    "inclusion_criteria": "1. Diagnosis and clinical course falling into one of the following categories:\n\n   1. Hodgkin lymphoma\n   2. Aggressive non-Hodgkin lymphoma\n   3. ALK-negative anaplastic T cell lymphoma or other peripheral T-cell lymphoma\n   4. ALK-positive anaplastic T cell lymphoma\n2. CD30-positive tumor as assayed in a CLIA certified Pathology Laboratory.\n3. Age 12 to 75.\n4. Bilirubin 2 times (or 3 times if the patient has Gilbert syndrome) or less than the upper limit of normal.\n5. AST 3 times or less than the upper limit of normal.\n6. Estimated GFR > 70 mL/min.\n7. Pulse oximetry of > 90% on room air\n8. EKG shows no significant arrhythmias\n9. Karnofsky or Lansky score of > 60%.\n10. Available allogeneic T cells with â‰¥15% expression of CD30CAR determined by flow-cytometry.\n11. Recovered from all acute non-hematologic toxic effects of all prior chemotherapy.\n12. Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded. The male partner should use a condom.\n13. Informed consent explained to, understood by and signed by patient or guardian. Patient or guardian given a copy of the informed consent form.\nHealthy volunteers allowed\nMust have minimum age of 12 Years\nMust have maximum age of 75 Years",
    "exclusion_criteria": "1. Received an investigational cell therapy or vaccine within the past 6 weeks.\n2. Received an investigational small molecule drug within the past 2 weeks.\n3. Received CD30 antibody-based therapy within the previous 4 weeks.\n4. Received gemcitabine-containing chemotherapy within the previous 12 weeks\n5. History of hypersensitivity reactions to murine protein-containing products.\n6. Pregnant or lactating.\n7. Tumor in a location where enlargement could cause airway obstruction (determined at the investigators' discretion).\n8. Current use of systemic corticosteroids at a dose equivalent to higher than 10 mg/day of prednisone.\n9. Active significant, uncontrolled bacterial, viral or fungal infection.\n10. Symptomatic cardiac disease (NYHA Class III or IV disease).",
    "miscellaneous_criteria": ""
}